[°ûÁöÇý] [±×·ì °è¿­»ç] mRNA Process Development ¸ðÁý

Date 07/02/2021   Hits 1700

1. ¼Ò¼Ó ÇìµåÇåÆÃ ȸ»ç¸í: Á¦ÀÌ¿¡ÀÌÄ¡¿¡ÀÌÄ¡¾Ë-JHHR /
ÁÖ¼Ò : ¼­¿ï½Ã °­¼­±¸ ¸¶°îÁß¾Ó 6·Î 21
2. ¼Ò¼Ó ÇìµåÇåÆÃ»ç ȨÆäÀÌÁö: http://www.jhhr.co.kr
3. ¼Ò¼Ó ÇìµåÇåÆÃ»ç ȸ»ç ÀüÈ­¹øÈ£: 82-2-567-7407 (Á÷Åë)
4. ¼Ò¼Ó ÇìµåÇåÆÃ»ç ȸ»ç¿ë, À̸ÞÀÏ : jhkwak@jhhr.co.kr
5. Æ÷Áö¼Ç ÁøÇà ÇìµåÇåÅÍ¸í ¹× Á÷±Þ : °û Áö Çý ´ëÇ¥ ÄÁ¼³ÅÏÆ®


[±×·ì °è¿­»ç] mRNA Process Development ¸ðÁý

1.ÀÇ·Ú»ç:[±×·ì °è¿­»ç] - Á¦¾à ¹× ¹ÙÀÌ¿À

¢Ã Position : [±×·ì °è¿­»ç] mRNA Process Development ¸ðÁý


[ÀÚ°Ý¿ä°Ç]

'- 5+ years of experience with mRNA process development and scale-up required.
'- Strong understanding of nucleic acid chemistry, enzymatic and chemical reactions, and mRNA process at bench and larger scales.
- Strong hands-on skills in nucleic acid handling and manipulation including plasmid preparation, in vitro transcription, purification, and cleanup is a must.
- Experience in the manufacture of biological products for clinical development.
- In-depth knowledge and proven experience working in a GMP and regulatory CMC environment.
- Strong collaborator with cross-functional teams and external partners
- Understanding of the in-vitro and in-vivo experiments and biological assays used for screening candidate formulations is a plus.
- Knowledge of nucleic acid chemistry and biology and standard methods of analysis of these molecules strongly preferred.
- Hands-on experience with liposomes or nanoparticles or other lipid-based drug delivery systems is a plus.
- Proficiency with Quality by Design (QbD) concepts, DoE, statistical process control (SPC) and complex data analysis is a plus.



[Á÷¹«³»¿ë]


- Strategic leader of one (or more) mRNA projects in the areas of immuno/oncology, infectious diseases or vaccination program
- Integration of company decisions and business considerations into the project
- Prioritization of program key objectives, data reviews and milestone deliverables
- Adapting the mRNA therapeutic property to the selected disease profile, increasing the chance of successful treatment in patients
- Monitoring changing regulatory requirements, as well as competitive landscape
- Collaboration within the mRNA group, as well across other functions
- As a team effort, identification of animal models for Non-GLP and GLP toxicology studies
- Demonstration of efficacy, durability and safety (especially immuno-safety) for innovative mRNA therapeutics and delivery vehicles, leading to identification of lead molecules within timelines
- Collect, analyze and document experimental data
- Present the final results to team members and line manager
- The successful candidate is expected to do hands-on bench work as requested




¢Ã Á¦Ãâ¼­·ù: ±¹¹® À̷¼­ ¹× »ó¼¼ °æ·Â ±â¼ú¼­

¢Ã ÁøÇàÀýÂ÷ : 1Â÷ ¼­·ù ÀüÇü- 2Â÷ ¸éÁ¢ÀüÇü - 3Â÷ ÃÖÁ¾¸éÁ¢

¢Ã ´ã´çÀÚ: °ûÁöÇý
¿¬¶ôó : 82-2-567-7407(Á÷Åë)
À̸ÞÀÏ : jhkwak@jhhr.co.kr